Use of Natriuretic Peptides as a Guidance for Treating Patients with Chronic Heart Failure: Unresolved Issues and Novel Insights
DOI:
https://doi.org/10.6000/1929-6029.2013.02.01.01Keywords:
B-type natriuretic peptides, natriuretic peptide-guided therapy, expert clinical assessment, chronic heart failureAbstract
Serial measurements of natriuretic peptides (NPs), i.e. B-type natriuretic peptide (BNP) or amino-terminal fragment of pro B-type natriuretic peptide (NT-pro BNP), may serve as an objective guide to modulate the intensity of drug treatment for individuals with chronic heart failure (CHF). However, considerable uncertainty remains about the alleged useful role of NP-guided therapy in this context. Particularly, which NP level should be assumed as optimal target level for therapy is still matter of debate. Actually, a too low predetermined cut off is encumbered with the risk of inducing a dose escalation perhaps not founded on solid rationale but provided with the potential of propitiating adverse medication effects that may be associated with higher doses. Conversely, a too high predetermined level for NP would entail a poor sensitivity, with the potential of excluding from higher doses of medications, that are proven to increase survival, just the patients who above all would have benefitted from this uptitration. Another much debated issue is constituted by possible age-related differences concerning the effects on clinical endpoints of NP-guided therapy. In addition, some Authors dispute about the possible advantages for the cardiovascular system arising from the functional activation of NPs in CHF patients, so denying that their increased levels have to be per se blamed for hemodynamic upheaval, especially in elder CHF patients.
After outlining the main RCTs carried out so far, the Authors stress the above reported issues and discuss the sometime contradictory results of the RCTs exploring NPs use as a guidance for therapy.
References
Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998; 135: 825-32. http://dx.doi.org/10.1016/S0002-8703(98)70041-9 DOI: https://doi.org/10.1016/S0002-8703(98)70041-9
Nakagawa O, Ogawa Y, Itoh H, Suga S, Komatsu Y, Kishimoto I, Nishino K, et al. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload. J Clin Invest 1995; 96: 1280-7. http://dx.doi.org/10.1172/JCI118162 DOI: https://doi.org/10.1172/JCI118162
O'Brien RJ, Squire IB, Demme B, Davies JE, Ng LL. Pre-discharge, but not admission, levels of NT-proBNP predict adverse prognosis following acute LVF. Eur J Heart Fail 2003; 5: 499-506. http://dx.doi.org/10.1016/S1388-9842(03)00098-9 DOI: https://doi.org/10.1016/S1388-9842(03)00098-9
Gackowski A, Isnard R, Golmard JL, Pousset F, Carayon A, Montalescot G, et al.Comparison of echocardiography and plasma B-type natriuretic peptide for monitoring the response to treatment in acute heart failure. Eur Heart J 2004; 25(20): 1788-96. http://dx.doi.org/10.1016/j.ehj.2004.07.038 DOI: https://doi.org/10.1016/j.ehj.2004.07.038
Maisel A, Mueller C, Adams K Jr, Anker SD, Aspromonte N, Cleland JG, et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008; 10: 824-39. http://dx.doi.org/10.1016/j.ejheart.2008.07.014 DOI: https://doi.org/10.1016/j.ejheart.2008.07.014
Wu AH, Smith A. Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure. Eur J Heart Fail 2004; 15; 6: 355-8. http://dx.doi.org/10.1016/j.ejheart.2003.12.011 DOI: https://doi.org/10.1016/j.ejheart.2003.12.011
O'Hanlon R, O'Shea P, Ledwidge M, et al. The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients. J Card Fail 2007; 13: 50-5 http://dx.doi.org/10.1016/j.cardfail.2006.09.003 DOI: https://doi.org/10.1016/j.cardfail.2006.09.003
Bruins S, Fokkema MR, Römer JW, Dejongste MJ, van der Dijs FP, van den Ouweland JM, et al. High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem Nov 2004; 50(11): 2052-8. http://dx.doi.org/10.1373/clinchem.2004.038752 DOI: https://doi.org/10.1373/clinchem.2004.038752
Wu AH. Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results. Am Heart J 2006; 152(5): 828-34. http://dx.doi.org/10.1016/j.ahj.2006.08.021 DOI: https://doi.org/10.1016/j.ahj.2006.08.021
Miller WL, Hartman KA, Grill DE, Burnett JC Jr, Jaffe AS. Only large reductions in concentrations of natriuretic peptides (BNP and NT-proBNP) are associated with improved outcome in ambulatory patients with chronic heart failure. Clin Chem 2009; 55(1): 78-84. http://dx.doi.org/10.1373/clinchem.2008.108928 DOI: https://doi.org/10.1373/clinchem.2008.108928
Mair J. “The utility of brain natriuretic peptides in patients with heart failure and coronary artery disease” in Adams JE III: Markers in cardiology: current and future clinical applications Chapter 20, pag 235-247 edited by Adams JE III, co-edited by Jaffe AS, Apple FS, Wu AHB, Futura Publishing Company, Armonk, New York 2001.
Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000; 355: 1126-30. http://dx.doi.org/10.1016/S0140-6736(00)02060-2 DOI: https://doi.org/10.1016/S0140-6736(00)02060-2
Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, Donal E, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 2007 24; 49: 1733-9. http://dx.doi.org/10.1016/j.jacc.2006.10.081 DOI: https://doi.org/10.1016/j.jacc.2006.10.081
Lainchbury JG, Troughton RW, Strangman KM, Frampton CM, Pilbrow A, Yandle TG, et al. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol 2009; 55(1): 53-60. DOI: https://doi.org/10.1016/j.jacc.2009.02.095
Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P, et al. TIME-CHF Investigators.BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 2009; 301(4): 383-92. DOI: https://doi.org/10.1001/jama.2009.2
Berger R, Moertl D, Peter S, Ahmadi R, Huelsmann M, Yamuti S, et al. N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study. J Am Coll Cardiol 2010; 55(7): 645-53. DOI: https://doi.org/10.1016/j.jacc.2009.08.078
Eurlings LW, van Pol PE, Kok WE, van Wijk S, Lodewijks-van der Bolt C, Balk AH, et al. Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. J Am Coll Cardiol 2010; 56(25): 2090-100. DOI: https://doi.org/10.1016/j.jacc.2010.07.030
Persson H, Erntell H, Eriksson B, Johansson G, Swedberg K, Dahlström U. Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NT-proBNP Guided Management of Heart Failure--SIGNAL-HF (Swedish Intervention study--Guidelines and NT-proBNP AnaLysis in Heart Failure). Eur J Heart Fail 2010; 12: 1300-8. http://dx.doi.org/10.1093/eurjhf/hfq169 DOI: https://doi.org/10.1093/eurjhf/hfq169
Shah MR, Califf RM, Nohria A, Bhapkar M, Bowers M, Mancini DM, et al. The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure. J Card Fail 2011; 17: 613-21. http://dx.doi.org/10.1016/j.cardfail.2011.04.012 DOI: https://doi.org/10.1016/j.cardfail.2011.04.012
Gaggin HK, Mohammed AA, Bhardwaj A, Rehman SU, Gregory SA, Weiner RB, et al. Heart Failure Outcomes and Benefits of NT-proBNP-Guided Management in the Elderly: Results From the Prospective, Randomized ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study. J Card Fail 2012; 18: 626-34. http://dx.doi.org/10.1016/j.cardfail.2012.05.005 DOI: https://doi.org/10.1016/j.cardfail.2012.05.005
Forman DE, Rich MW, Alexander KP, Zieman S, Maurer MS, Najjar SS, et al. Cardiac care for older adults. Time for a new paradigm. J Am Coll Cardiol 2011; 57(18): 1801-10. http://dx.doi.org/10.1016/j.jacc.2011.02.014 DOI: https://doi.org/10.1016/j.jacc.2011.02.014
Troughton RW, Frampton CM, Nicholls MG. Biomarker-guided treatment of heart failure: still waiting for a definitive answer. J Am Coll Cardiol 2010; 56(25): 2101-4. http://dx.doi.org/10.1016/j.jacc.2010.07.034 DOI: https://doi.org/10.1016/j.jacc.2010.07.034
Luchner A, Stevens TL, Borgeson DD, Redfield M, Wei CM, Porter JG, Burnett JC Jr. Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol 1998; 274(5 Pt 2): H1684-9. DOI: https://doi.org/10.1152/ajpheart.1998.274.5.H1684
Shimizu H, Masuta K, Aono K, Asada H, Sasakura K, Tamaki M, et al. Molecular forms of human brain natriuretic peptide in plasma. Clin Chim Acta 2002; 316(1-2): 129-35. http://dx.doi.org/10.1016/S0009-8981(01)00745-8 DOI: https://doi.org/10.1016/S0009-8981(01)00745-8
Hawkridge AM, Heublein DM, Bergen HR 3rd, Cataliotti A, Burnett JC Jr., Muddiman DC. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci USA 2005; 102: 17442-7. http://dx.doi.org/10.1073/pnas.0508782102 DOI: https://doi.org/10.1073/pnas.0508782102
Liang F, O'Rear J, Schellenberger U, Tai L, Lasecki M, Schreiner GF, et al. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol 2007; 13; 49(10): 1071-8. DOI: https://doi.org/10.1016/j.jacc.2006.10.063
Lam CS, Burnett Jr JC, Costello-Boerrigter L, Rodeheffer RJ, Redfield MM. Alternate circulating pro-B-type natriuretic
peptide and B-type natriuretic peptide forms in the general population. J Am Coll Cardiol 2007; 49: 1193-202. http://dx.doi.org/10.1016/j.jacc.2006.12.024 DOI: https://doi.org/10.1016/j.jacc.2006.12.024
Chen HH, Schirger JA, Chau WL, Jougasaki M, Lisy O, Redfield MM, et al. Renal response to acute neutral endopeptidase inhibition in mild and severe experimental heart failure. Circulation 1999; 100(24): 2443-8. DOI: https://doi.org/10.1161/01.CIR.100.24.2443
Charloux A, Piquard F, Doutreleau S, Brandenberger G, Geny B. Mechanisms of renal hyporesponsiveness to ANP in heart failure. Eur J Clin Invest 2003; 33: 769-78. http://dx.doi.org/10.1046/j.1365-2362.2003.01222.x DOI: https://doi.org/10.1046/j.1365-2362.2003.01222.x
Miller WL, Hartman KA, Burritt MF, Borgeson DD, Burnett JC Jr, Jaffe AS. Biomarker responses during and after treatment with nesiritide infusion in patients with decompensated chronic heart failure. Clin Chem 2005; 51: 569-77. http://dx.doi.org/10.1373/clinchem.2004.041582 DOI: https://doi.org/10.1373/clinchem.2004.041582
Raymond I, Groenning BA, Hildebrandt PR, Nilsson JC, Baumann M, Trawinski J, et al. The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 2003; 89: 745-51. http://dx.doi.org/10.1136/heart.89.7.745 DOI: https://doi.org/10.1136/heart.89.7.745
Rademaker MT, Charles CJ, Kosoglou T, Protter AA, Espiner EA, Nicholls MG, et al. Clearance receptors and endopeptidase: equal role in natriuretic peptide metabolism in heart failure. Am J Physiol 1997; 273: H2372-9. DOI: https://doi.org/10.1152/ajpheart.1997.273.5.H2372
Potter LR, Hunter T. Guanylyl cyclase-linked natriuretic peptide receptors: structure and regulation. J Biol Chem 2001; 276: 6057-60. http://dx.doi.org/10.1074/jbc.R000033200 DOI: https://doi.org/10.1074/jbc.R000033200
Packer M. Should B-type natriuretic peptide be measured routinely to guide the diagnosis and management of chronic heart failure? Focused perspective. Circulation 2003; 108: 2950-3. http://dx.doi.org/10.1161/01.CIR.0000109205.35813.8E DOI: https://doi.org/10.1161/01.CIR.0000109205.35813.8E
MacFadyen RJ, Ng Kam Chuen MJ, Davis RC. Loop diuretic therapy in left ventricular systolic dysfunction: has familiarity bred contempt for a critical but potentially nephrotoxic cardio renal therapy? Eur J Heart Fail 2010; 12: 649-52. http://dx.doi.org/10.1093/eurjhf/hfq104 DOI: https://doi.org/10.1093/eurjhf/hfq104
Ronco C, Haapio M, House AA, Anavekar N, Bellomo R.Cardiorenal syndrome. J Am Coll Cardiol 2008; 52(19): 1527-39. http://dx.doi.org/10.1016/j.jacc.2008.07.051 DOI: https://doi.org/10.1016/j.jacc.2008.07.051
Felker GM, Hasselblad V, Hernandez AF, O’Connor CM. Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J 2009; 158: 422-30. http://dx.doi.org/10.1016/j.ahj.2009.06.018 DOI: https://doi.org/10.1016/j.ahj.2009.06.018
Porapakkham P, Zimmet H, Billah B, Krum H. B-type natriuretic peptide-guided heart failure therapy: a meta-analysis. Arch Intern Med 2010; 170: 507-14. http://dx.doi.org/10.1001/archinternmed.2010.35 DOI: https://doi.org/10.1001/archinternmed.2010.35
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2013 Renato De Vecchis, Claudia Esposito
This work is licensed under a Creative Commons Attribution 4.0 International License.
Policy for Journals/Articles with Open Access
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work
Policy for Journals / Manuscript with Paid Access
Authors who publish with this journal agree to the following terms:
- Publisher retain copyright .
- Authors are permitted and encouraged to post links to their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work .
